SAN FRANCISCO--(BUSINESS WIRE)--Menten AI, Inc., a biotechnology company with a generative AI platform for design and optimization of peptide macrocycles, today announced the completion of a previously undisclosed research collaboration and licensing agreement with Bristol Myers Squibb applying Menten AI’s platform for optimization of cyclic peptides..

旧金山--（商业新闻短讯）--拥有用于设计和优化肽大环化合物的生成性人工智能平台的生物技术公司Menten AI，Inc.今天宣布，与百时美施贵宝（Bristol-Myers Squibb）完成了一项先前未公开的研究合作和许可协议，该协议将应用Menten AI的环肽优化平台。。

Menten AI’s platform combines state-of-the-art machine learning techniques with physics-based models and quantum chemistry simulations to accelerate the design and optimization of peptide macrocycles. Rather than screening through libraries of millions of molecules, the Menten AI platform uses generative AI to effectively create a shortcut through the chemical space to identify macrocycles with the right properties.

Menten AI的平台将最先进的机器学习技术与基于物理的模型和量子化学模拟相结合，以加速肽大环的设计和优化。Menten AI平台不是通过数百万个分子的文库进行筛选，而是使用生成AI有效地在化学空间中创建一条捷径，以识别具有正确性质的大环化合物。

This significantly reduces the number of candidate molecules that need to be tested in the wet lab as well as the overall number of iterations required to achieve drug-like properties..

这大大减少了需要在湿实验室中测试的候选分子数量，以及实现类似药物特性所需的总迭代次数。。

Under the research collaboration, Menten AI and Bristol Myers Squibb leveraged Menten AI’s generative AI platform and team’s expertise to optimize the biochemical properties of certain peptide macrocycles. Together, the teams were able to explore a more expansive chemical space and identified new amino acid modifications to improve the desired properties.

在研究合作下，Menten AI和百时美施贵宝利用Menten AI的生成AI平台和团队的专业知识来优化某些肽大环的生化特性。这些团队共同探索了一个更广阔的化学空间，并确定了新的氨基酸修饰以改善所需的性质。

“This is a key milestone for Menten AI, as it demonstrates the maturity of our platform, and of generative AI more broadly, to accelerate the discovery and optimization of next-generation peptide macrocycles,” noted Hans Melo, co-founder and CEO of Menten AI.

Menten AI联合创始人兼首席执行官汉斯·梅洛（Hans Melo）表示：“这是Menten AI的一个关键里程碑，因为它证明了我们平台以及更广泛的生成AI的成熟，以加速下一代肽大环的发现和优化。”。

About Menten AI, Inc.

关于Menten AI，Inc。

Menten AI is developing generative AI to design next-generation cyclic peptide therapeutics for challenging drug targets beyond the reach of small molecules and biologics. Its proprietary platform can design potent and membrane-permeable peptide macrocycles in a matter of weeks. The team has shown in vitro and in vivo validation of their platform for complex drug targets including protein-protein interfaces (PPIs).

Menten AI正在开发生成性AI，以设计下一代环肽疗法，用于挑战小分子和生物制剂无法达到的药物靶标。它的专有平台可以在几周内设计出有效且可膜渗透的肽大环化合物。该团队已经在体外和体内验证了他们的复杂药物靶标平台，包括蛋白质-蛋白质界面（PPI）。

The company has partnerships with top-10 pharma to support and accelerate their preclinical drug discovery efforts. Menten AI is backed by top VCs including Social Impact Capital, Uncork Capital, Khosla Ventures, and Y-Combinator..

该公司与十大制药公司建立了合作伙伴关系，以支持和加速其临床前药物发现工作。Menten AI拥有顶级风投的支持，包括Social Impact Capital、Uncork Capital、Khosla Ventures和Y-Combinator。。